Network modelling reveals the mechanism underlying colitis-associated colon cancer and identifies novel combinatorial anti-cancer targets

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lu, Junyan ^a   Zeng, Hanlin ^a   Liang, Zhongjie ^b   Chen, Limin ^a   Zhang, Liyi ^a   Zhang, Hao ^a   Liu, Hong ^a   Jiang, Hualiang ^a   Shen, Bairong ^b   Huang, Ming ^a   Geng, Meiyu ^a   Spiegel, Sarah ^c   Luo, Cheng ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SOOCHOW UNIVERSITY   (China)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE; MDM2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53;

ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL TRANSFORMATION; COLITIS; COLON; COLONIC NEOPLASMS; COMPLICATION; COMPUTER SIMULATION; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CERAMIDES; COLITIS; COLON; COLONIC NEOPLASMS; COMPUTER SIMULATION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MODELS, GENETIC; MOLECULAR TARGETED THERAPY; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84943617803     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14739     Document Type: Article

References (59)

1. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545, doi: 10.1016/S0140-6736(00)04046-0 (2001).
2. Garagnani, P., Pirazzini, C. & Franceschi, C. Colorectal cancer microenvironment: among nutrition, gut Microbiota, inflammation and epigenetics. Curr Pharm Design 19, 765-778 (2013).
3. Ekbom, A., Helmick, C., Zack, M. & Adami, H. O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336, 357-359 (1990).
4. Giardiello, F. M., Offerhaus, G. J. & DuBois, R. N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 31A, 1071-1076 (1995).
5. Lin, W. W. & Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117, 1175-1183, doi: 10.1172/Jci31537 (2007).
6. Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51, doi: 10.1038/Nri1995 (2007).
7. Greten, F. R. et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296, doi: 10.1016/j.cell.2004.07.013 (2004).
8. Bierie, B. & Moses, H. L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine & growth factor reviews 21, 49-59, doi: 10.1016/j.cytogfr.2009.11.008 (2010).
9. Wang, D. & Dubois, R. N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29, 781-788, doi: 10.1038/onc.2009.421 (2010).
10. de Visser, K. E. & Jonkers, J. Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr Pharm Des 15, 1844-1853 (2009).
11. Choi, M., Shi, J., Jung, S. H., Chen, X. & Cho, K. H. Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to dNA damage. Sci Signal 5, ra83, doi: 10.1126/scisignal.2003363 (2012).
12. Singh, A., Nascimento, J. M., Kowar, S., Busch, H. & Boerries, M. Boolean approach to signalling pathway modelling in HGFinduced keratinocyte migration. Bioinformatics 28, I495-I501, doi: 10.1093/bioinformatics/bts410 (2012).
13. Zhang, R. R. et al. Network model of survival signaling in large granular lymphocyte leukemia. Proceedings of the National Academy of Sciences of the United States of America 105, 16308-16313, doi: 10.1073/pnas.0806447105 (2008).
14. Naldi, A., Carneiro, J., Chaouiya, C. & Thieffry, D. Diversity and plasticity of Th cell types predicted from regulatory network modelling. PLoS computational biology 6, e1000912, doi: 10.1371/journal.pcbi.1000912 (2010).
15. Saez-Rodriguez, J. et al. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer research 71, 5400-5411 (2011).
16. Fumia, H. F. & Martins, M. L. Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes. Plos One 8, e69008, doi: 10.1371/journal.pone.0069008 (2013).
17. Morin, P. J. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275, 1787-1790 (1997).
18. Kojima, M. et al. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 24, 675-681 (2004).
19. Atreya, R. & Neurath, M. F. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 28, 187-196 (2005).
20. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798-809, doi: 10.1038/Nrc2734 (2009).
21. Saadatpour, A., Albert, I. & Albert, R. Attractor analysis of asynchronous Boolean models of signal transduction networks. Journal of theoretical biology 266, 641-656, doi: 10.1016/j.jtbi.2010.07.022 (2010).
22. Potten, C. S. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metastasis Rev 11, 179-195 (1992).
23. Rescigno, M. & Di Sabatino, A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest 119, 2441-2450, doi: 10.1172/JCI39134 (2009).
24. Fiocchi, C. The normal intestinal mucos: a state of 'controlled inflammation' in Inflammatory bowel disease: from bench to bedside (ed Fergus Shanahan Loren C. Karp, Stephan R. Targan) Ch. 8, 101-120 (Springer, 2005).
25. Hart, A. L. et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129, 50-65 (2005).
26. MacDonald, T. T. Cytokine regulation of intestinal epithelial cell proliferation. Expert Rev Clin Immunol 6, 531-535, doi: 10.1586/eci.10.42 (2010).
27. Erdman, S. E. et al. CD4+ CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65, 3998-4004 (2005).
28. Waldner, M. J. & Neurath, M. F. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31, 249-256, doi: 10.1007/s00281-009-0161-8 (2009).
29. Naito, Y. et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58, 3491-3494 (1998).
30. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113, doi: 10.1016/j.ccr.2009.01.001 (2009).
31. Redston, M. S., Papadopoulos, N., Caldas, C., Kinzler, K. W. & Kern, S. E. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 108, 383-392 (1995).
32. Tarmin, L. et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 55, 2035-2038 (1995).
33. Aust, D. E. et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer-Am Cancer Soc 94, 1421-1427 (2002).
34. Broom, O. J., Widjaya, B., Troelsen, J., Olsen, J. & Nielsen, O. H. Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 158, 272-280 (2009).
35. Fang, J. Y. & Richardson, B. C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6, 322-327 (2005).
36. Bos, J. L. et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297, doi: 10.1038/327293a0 (1987).
37. Itoh, N. et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer-Am Cancer Soc 94, 3127-3134, doi: 10.1002/Cncr.10591 (2002).
38. Khan, M. W. et al. PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer. Clin Cancer Res 19, 2342-2354, doi: 10.1158/1078-0432.Ccr-12-2623 (2013).
39. Rubin, D. C., Shaker, A. & Levin, M. S. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 3, 107, doi: 10.3389/fimmu.2012.00107 (2012).
40. Yan, F. et al. Kinase suppressor of Ras-1 protects intestinal epithelium from cytokine-mediated apoptosis during inflammation. J Clin Invest 114, 1272-1280, doi: 10.1172/JCI21022 (2004).
41. Becker, C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501, doi: 10.1016/j.immuni.2004.07.020 (2004).
42. Liang, J. et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23, 107-120, doi: 10.1016/j.ccr.2012.11.013 (2013).
43. Martini, M., De Santis, M. C., Braccini, L., Gulluni, F. & Hirsch, E. PI3K/AKT signaling pathway and cancer: an updated review. Annals of medicine 46, 372-383, doi: 10.3109/07853890.2014.912836 (2014).
44. Haimovitz-Friedman, A., Kolesnick, R. N. & Fuks, Z. Ceramide signaling in apoptosis. British medical bulletin 53, 539-553 (1997).
45. Litvak, D. A., Bilchik, A. J. & Cabot, M. C. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 7, 140-148 (2003).
46. Ahmed, D. et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2, e71, doi: 10.1038/oncsis.2013.35 (2013).
47. Ogretmen, B. et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem 277, 12960-12969, doi: 10.1074/jbc.M110699200 (2002).
48. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes & development 18, 1926-1945, doi: 10.1101/gad.1212704 (2004).
49. Lim, K. G. et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 286, 18633-18640, doi: 10.1074/jbc.M111.220756 (2011).
50. Chen, L. et al. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels. Plos One 9, e103033, doi: 10.1371/journal.pone.0103033 (2014).
51. Colombini, M. Ceramide channels and their role in mitochondria-mediated apoptosis. Bba-Bioenergetics 1797, 1239-1244, doi: 10.1016/j.bbabio.2010.01.021 (2010).
52. Dobrowsky, R. T., Kamibayashi, C., Mumby, M. C. & Hannun, Y. A. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 268, 15523-15530 (1993).
53. Stiles, B. L. PI-3-K and AKT: Onto the mitochondria. Advanced drug delivery reviews 61, 1276-1282, doi: 10.1016/j. addr.2009.07.017 (2009).
54. Casson, L. et al. Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. Plos One 8, e54525, doi: 10.1371/journal.pone.0054525 (2013).
55. Kachalo, S., Zhang, R., Sontag, E., Albert, R. & DasGupta, B. NET-SYNTHESIS: a software for synthesis, inference and simplification of signal transduction networks. Bioinformatics 24, 293-295, doi: 10.1093/bioinformatics/btm571 (2008).
56. Albert, I., Thakar, J., Li, S., Zhang, R. & Albert, R. Boolean network simulations for life scientists. Source code for biology and medicine 3, 16, doi: 10.1186/1751-0473-3-16 (2008).
57. Harvey, I. & Bossomaier, T. Time out of joint: Attractors in asynchronous random boolean networks (MIT Press, Cambridge, 1997).
58. Chaves, M., Albert, R. & Sontag, E. D. Robustness and fragility of Boolean models for genetic regulatory networks. Journal of theoretical biology 235, 431-449, doi: 10.1016/j.jtbi.2005.01.023 (2005).
59. Saadatpour, A. & Albert, R. Boolean modeling of biological regulatory networks: a methodology tutorial. Methods 62, 3-12, doi: 10.1016/j.ymeth.2012.10.012 (2013).